TROPHY-U-01: Sacituzumab Govitecan for Platinum-ineligible Metastatic UC
By Daniel P. Petrylak, MD - Last Updated: February 18, 2023Daniel P. Petrylak, MD, a Professor of Medicine and Urology at the Yale School of Medicine, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic urothelial carcinoma who have progressed on checkpoint inhibitor therapy.
Post Tags:ASCO GU 2023-Bladder Cancer
Related Posts
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
670 Madison Ave.
Manalapan, NJ 07726